BioSpace News Archive

It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

U.S. District Judge Colleen McMahon rejected a bankruptcy plan that shielded the Sackler family from potential lawsuits related to the opioid crisis.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that it has entered into a strategic collaboration with Vaneltix Pharma, Inc. for the development and commercialisation of AlenuraTM as first-line drug treatment for acute pain in interstitial cystitis /bladder pain syndrome.

Addex Therapeutics Ltd announced that it has entered into a definitive agreement with Armistice Capital LLC, a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares at a gross purchase price of $6.50 per ADS, which is equivalent to CHF 1.00 per share.

Roche announced that its cobas® SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas® 6800/8800 Systems.

Iktos, a company specialized in Artificial Intelligence for new drug design, and The Drug Discovery Unit today announced entering a collaboration to apply Iktos’s generative modelling artificial intelligence (AI).

Funds advised by SK Capital Partners (“SK Capital”), a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, today announced the acquisition of a majority shareholding in SEQENS (the “Company”), one of the world’s leading pharmaceutical solutions and specialty ingredients companies.

Sonnet BioTherapeutics Holdings, Inc. announced today its financial results for the fiscal year ended September 30th , 2021 and provided a business update.

Ipsen and GENFIT, have entered into a long-term strategic partnership for global collaboration between the two companies.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that it will attend the following upcoming virtual investor conferences.